X-linked hypophosphatemic rickets with advanced bone age treated with aromatase inhibitor
We present an adolescent with X-linked hypophosphatemic rickets (XLH) with bone age advancement and its response to aromatase inhibitors (AIs). A male with XLH, confirmed with a deletion on the PHEX gene, received regular treatment since the first year of life with average growth velocity and height...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2023-05-01
|
| Series: | Endocrine Connections |
| Online Access: | https://edm.bioscientifica.com/view/journals/edm/2023/2/EDM23-0005.xml |
| _version_ | 1797829337126273024 |
|---|---|
| author | João Felipe Queiroz Soraya Lopes Sader Carina Marques Barroso Guido de Paula Colares Neto |
| author_facet | João Felipe Queiroz Soraya Lopes Sader Carina Marques Barroso Guido de Paula Colares Neto |
| author_sort | João Felipe Queiroz |
| collection | DOAJ |
| description | We present an adolescent with X-linked hypophosphatemic rickets (XLH) with bone age advancement and its response to aromatase inhibitors (AIs). A male with XLH, confirmed with a deletion on the PHEX gene, received regular treatment since the first year of life with average growth velocity and height. He had bone age compatible with chronological age until 13 when he had a bone age advancement and a decrease in the predicted final height thought to be due to initiation of oral isotretinoin, which has been previously reported. Then, anastrozole was initiated and maintained concomitant to the rickets treatment for 2 years with bone age stabilization. He had no adverse effects or worsening of bone health markers. As a result, he maintained his height gain and improved his final height Z score compared with the predicted final height at initiating anastrozole. In conclusion, although AIs was a reasonable strategy to stabilize bone age and minimize height impairment, careful monitoring is mandatory to understand its benefits and effects on XLH patients. |
| first_indexed | 2024-04-09T13:18:50Z |
| format | Article |
| id | doaj.art-5daeb73831bd46929798ca94fe07cd28 |
| institution | Directory Open Access Journal |
| issn | 2049-3614 |
| language | English |
| last_indexed | 2024-04-09T13:18:50Z |
| publishDate | 2023-05-01 |
| publisher | Bioscientifica |
| record_format | Article |
| series | Endocrine Connections |
| spelling | doaj.art-5daeb73831bd46929798ca94fe07cd282023-05-11T10:35:55ZengBioscientificaEndocrine Connections2049-36142023-05-01111510.1530/EDM-23-0005X-linked hypophosphatemic rickets with advanced bone age treated with aromatase inhibitorJoão Felipe Queiroz0Soraya Lopes Sader1Carina Marques Barroso2Guido de Paula Colares Neto3Universidade de Fortaleza, Av. Washington Soares, Fortaleza, CE, Ceará, BrazilUniversidade de São Paulo, Av. Bandeirantes, Monte Alegre, Ribeirão Preto, SP, BrazilHospital Infantil Albert Sabin, R. Tertuliano Sales, Fortaleza, CE, Ceará, BrazilCentro Universitário São Camilo, Faculdade de Medicina. Avenida Nazaré, São Paulo, SP, BrasilWe present an adolescent with X-linked hypophosphatemic rickets (XLH) with bone age advancement and its response to aromatase inhibitors (AIs). A male with XLH, confirmed with a deletion on the PHEX gene, received regular treatment since the first year of life with average growth velocity and height. He had bone age compatible with chronological age until 13 when he had a bone age advancement and a decrease in the predicted final height thought to be due to initiation of oral isotretinoin, which has been previously reported. Then, anastrozole was initiated and maintained concomitant to the rickets treatment for 2 years with bone age stabilization. He had no adverse effects or worsening of bone health markers. As a result, he maintained his height gain and improved his final height Z score compared with the predicted final height at initiating anastrozole. In conclusion, although AIs was a reasonable strategy to stabilize bone age and minimize height impairment, careful monitoring is mandatory to understand its benefits and effects on XLH patients.https://edm.bioscientifica.com/view/journals/edm/2023/2/EDM23-0005.xml |
| spellingShingle | João Felipe Queiroz Soraya Lopes Sader Carina Marques Barroso Guido de Paula Colares Neto X-linked hypophosphatemic rickets with advanced bone age treated with aromatase inhibitor Endocrine Connections |
| title | X-linked hypophosphatemic rickets with advanced bone age treated with aromatase inhibitor |
| title_full | X-linked hypophosphatemic rickets with advanced bone age treated with aromatase inhibitor |
| title_fullStr | X-linked hypophosphatemic rickets with advanced bone age treated with aromatase inhibitor |
| title_full_unstemmed | X-linked hypophosphatemic rickets with advanced bone age treated with aromatase inhibitor |
| title_short | X-linked hypophosphatemic rickets with advanced bone age treated with aromatase inhibitor |
| title_sort | x linked hypophosphatemic rickets with advanced bone age treated with aromatase inhibitor |
| url | https://edm.bioscientifica.com/view/journals/edm/2023/2/EDM23-0005.xml |
| work_keys_str_mv | AT joaofelipequeiroz xlinkedhypophosphatemicricketswithadvancedboneagetreatedwitharomataseinhibitor AT sorayalopessader xlinkedhypophosphatemicricketswithadvancedboneagetreatedwitharomataseinhibitor AT carinamarquesbarroso xlinkedhypophosphatemicricketswithadvancedboneagetreatedwitharomataseinhibitor AT guidodepaulacolaresneto xlinkedhypophosphatemicricketswithadvancedboneagetreatedwitharomataseinhibitor |